It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alternative Lengthening of Telomeres (ALT) is an aberrant DNA recombination pathway which grants replicative immortality to approximately 10% of all cancers. Despite this high prevalence of ALT in cancer, the mechanism and genetics by which cells activate this pathway remain incompletely understood. A major challenge in dissecting the events that initiate ALT is the extremely low frequency of ALT induction in human cell systems. Guided by the genetic lesions that have been associated with ALT from cancer sequencing studies, we genetically engineered primary human pluripotent stem cells to deterministically induce ALT upon differentiation. Using this genetically defined system, we demonstrate that disruption of the p53 and Rb pathways in combination with ATRX loss-of-function is sufficient to induce all hallmarks of ALT and results in functional immortalization in a cell type-specific manner. We further demonstrate that ALT can be induced in the presence of telomerase, is neither dependent on telomere shortening nor crisis, but is rather driven by continuous telomere instability triggered by the induction of differentiation in ATRX-deficient stem cells.
Mutations of ATRX are frequent in cancers that immortalize through the ALT (Alternative lengthening of telomeres) pathway. Here the authors show that ALT features are repressed in embryonic stem cells that lack ATRX but induced by continuous telomere instability triggered upon cell differentiation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of California, Department of Molecular and Cell Biology, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)
2 Dovetail Genomics, Scotts Valley, USA (GRID:grid.504403.6)
3 University of Groningen, University Medical Centre Groningen, European Research Institute for the Biology of Ageing, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
4 BC Cancer Agency, Terry Fox Laboratory, Vancouver, Canada (GRID:grid.248762.d) (ISNI:0000 0001 0702 3000); University of British Columbia, Department of Medical Genetics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
5 University of California, Department of Molecular and Cell Biology, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878); Chan Zuckerberg Biohub, San Francisco, USA (GRID:grid.499295.a) (ISNI:0000 0004 9234 0175); University of California, Innovative Genomics Institute, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)